Study directory

Schizophrenia studies

Compare studies and check their requirements with the research team.

4306studies shown

Showing 1,729-1,740 of 4,306

CompletedEUCTR 2015-004835-10

A 52-Week, Open-Label, Prospective, Multicenter, International Study of a Transition to the Paliperidone Palmitate 3-Month Formulation In Patients with Schizophrenia Previously Stabilized on the Pa...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Croatia

Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug

Countries: United Kingdom, Croatia, Denmark, ...
Sponsor: Janssen-Cilag International NV
Condition: Schizophrenia

View study

CompletedEUCTR 2004-002185-38

A 6 months double-blind, risperidone-referenced, flexible dose, parallel-group extension study of bifeprunox in patients with schizophrenia

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Spain

Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug

Countries: Spain
Sponsor: H.Lundbeck A/S
Condition: Schizophrenia

View study

CompletedEUCTR 2010-022181-28

A 6-month, randomised, double-blind, parallel-group, risperidone-controlled, fixed-dose study evaluating the safety and efficacy of zicronapine in patients with schizophrenia

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Czech Republic

Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug

Countries: Czechia, Estonia, Finland, ...
Sponsor: H. Lundbeck A/S
Condition: Schizophrenia

View study

CompletedEUCTR 2016-000060-42

A 6-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lurasidone (SM-13496) in Acutely Psychotic Subjects with Schizophrenia

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Poland

Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug

Countries: Poland, Slovakia
Sponsor: Sunovion Pharmaceuticals Inc.
Condition: Schizophrenia

View study

CompletedEUCTR 2007-004482-18

A blinded-initiation study of medication satisfaction in subjects with schizophrenia treated with paliperidone ER after suboptimal response to oral risperidone.

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Czech Republic

Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug

Countries: Czechia, Slovakia
Sponsor: Ortho-McNeil Janssen Scientific Affairs, LLC
Condition: Schizophrenia

View study

CompletedEUCTR 2011-001711-31

A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance treatment of subjects with schizophrenia

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Italy

Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug

Countries: Italy, Slovakia
Sponsor: Sunovion Pharmaceuticals Inc.
Condition: Schizophrenia

View study

TerminatedEUCTR 2005-005499-34

A double-blind, randomised, placebo-controlled, quetiapine-referenced, multicentre study of the long-term bifeprunox efficacy, safety and tolerability in patiens with stable schizophrenia

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Greece

Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug

Countries: Greece
Sponsor: H. Lundbeck A/S
Condition: Schizophrenia

View study

TerminatedEUCTR 2010-018911-13

A Long-term, Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Flexible-Dose Oral Aripiprazole (OPC-14597) as Maintenance Treatment in Adolescent Patients with Schizophrenia...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Bulgaria

Why is this study shown?

This study is directly about Schizophrenia.

Schizophrenia, BipolarityDrug

Countries: Bulgaria, Hungary, Poland
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition: Schizophrenia, Bipolarity

View study

CompletedEUCTR 2009-017853-36

A Long-Term, Open-Label, Multicenter Study of LY2140023 Compared to Atypical Antipsychotic Standard of Care in Patients with DSM-IV-TR Schizophrenia

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Germany

Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug

Countries: Germany
Sponsor: Eli Lilly and Company
Condition: Schizophrenia

View study

CompletedEUCTR 2008-007307-91

A Long-Term, Phase 2, Multicenter, Randomized, Open-Label, Comparative Safety Study of LY2140023 Versus Atypical Antipsychotic Standard of Care in Patients with DSM-IV-TR Schizophrenia

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Germany

Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug

Countries: Germany
Sponsor: Eli Lilly and Company
Condition: Schizophrenia

View study

CompletedEUCTR 2011-002514-37

A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Maintenance Treatment in Adults with Schizophrenia

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Latvia

Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug

Countries: Latvia, Poland, Slovakia
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition: Schizophrenia

View study

CompletedEUCTR 2007-000800-34

A Multi-center, Inpatient, Phase 2, Double-blind, Placebo-controlled Dose Ranging Study of LY2140023 in Patients with DSM-IV Schizophrenia.

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Austria

Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug

Countries: Austria, Germany, Portugal
Sponsor: Eli Lilly and Company Ltd.
Condition: Schizophrenia

View study

Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.